Novo says C-peptide is not their target
Posted Aug 23rd 2007 10:51AM by Allie Beatty
Filed under: Type 1, Childhood, Drugs, Research, Opinion, Allie Beatty, Retro Review, Personalities, Form and Function
I contacted Novo Nordisk back in March to tell them about the remarkable effects C-peptide had on reversing complications of Type 1 diabetes. I asked if they would bring the drug to market. A mass of excitement overwhelmed me when I learned about C-peptide missing from insulin all these years. The response from Novo? No thanks, it's not one of our targets. Targets, eh?
C-peptide is a byproduct of the production of insulin. In Type 1 diabetics, the level of C-peptide eventually becomes undetectable due to the body not making any insulin of its own. Long-term complications of diabetes frequently develop despite insulin therapy and optimal blood glucose control. C-peptide could quite possibly be the missing link in perfect diabetes control. I sent the following document to Novo Nordisk and asked them to make C-peptide available to reverse and ameliorate renal and nerve dysfunction for Type 1 diabetics. Read the document and see for yourself the eye-popping beneficial results C-peptide offers Type 1 diabetics. I received it directly from Dr. Wahren, lead researcher for C-peptide.
After 5 months consideration, Novo called me back. They said C-peptide is not a target for their company. I understand and now Levemir is not a target in my diabetes control, either. For all the Type 1 diabetics out there controlling your sugars with insulin not really made with you in mind -- do you understand why Novo does not wish to develop this critically important treatment? I guess insulin is good enough, right? Wrong. It's a tough job but somebody's got to do it. Just not Novo. When you are in the business of diabusiness -- no thank you says so much about what could potentially hurt your business.
Tags: allie beatty, AllieBeatty, Big Pharma not interested in C-peptide, BigPharmaNotInterestedInC-peptide, bioactive incorrecting diabetes complicatoins, BioactiveIncorrectingDiabetesComplicatoins, bite the hand that feeds you, BiteTheHandThatFeedsYou, c-peptide, C-peptide is a bioactive peptide, C-peptideIsABioactivePeptide, complications due to diabetes, ComplicationsDueToDiabetes, correct diabetes complications, correct diabetic complications, CorrectDiabetesComplications, CorrectDiabeticComplications, correcting complications of diabetes, correcting diabetes complications, correcting insulin imbalance, CorrectingComplicationsOfDiabetes, CorrectingDiabetesComplications, CorrectingInsulinImbalance, could c-peptide define a cure for diabetes?, CouldC-peptideDefineACureForDiabetes?, curious disinterest in an interesting MISSING LINK, CuriousDisinterestInAnInterestingMissingLink, diabusiness, dr. john wahren, Dr.JohnWahren, Endothelial nitric oxide synthase, EndothelialNitricOxideSynthase, fix diabetes complications, fix renal function, FixDiabetesComplications, fixing GFR, FixingGfr, FixRenalFunction, G-protein, Glomerular filtration rate, GlomerularFiltrationRate, human target, HumanTarget, Insulin, kidney damage, KidneyDamage, killing Big Pharma, killing diabusiness, KillingBigPharma, KillingDiabusiness, Krebs Cycle and diabetes, KrebsCycleAndDiabetes, leading diabetes consumer advocate, leading diabetes online blog, LeadingDiabetesConsumerAdvocate, LeadingDiabetesOnlineBlog, LoveDiabetes, Membrane binding, MembraneBinding, Microalbuminuria, Na /K -ATPase ., Na /k -atpase., NCV, Nerve conduction velocity, nerve damage, NerveConductionVelocity, NerveDamage, not a target, NotATarget, Novo C-peptide is not their target, Novo does not wish to help type 1 diabetics, Novo doesn't care about Type 1 diabetics, Novo Nordisk is in the business, Novo says no thanks to C-peptide, NovoC-peptideIsNotTheirTarget, NovoDoesn'tCareAboutType1Diabetics, NovoDoesNotWishToHelpType1Diabetics, NovoNordiskIsInTheBusiness, NovoSaysNoThanksToC-peptide, popular diabetes blog, PopularDiabetesBlog, Red blood cell, RedBloodCell, renal function, RenalFunction, secret to recovering from diabetes, SecretToRecoveringFromDiabetes, Shop4Cures, sodium potassium, SodiumPotassium, thank you card, ThankYouCard, the goose that laid the golden egg, TheGooseThatLaidTheGoldenEgg, Type 1 is not a Novo target, Type1IsNotANovoTarget, what does Glomerular filtration ratemean?, WhatDoesGlomerularFiltrationRatemean?, why wouldn't Novo want to help correct diabetes complications, WhyWouldn'tNovoWantToHelpCorrectDiabetesComplications
1. I have asked Creative Peptides for an interview, and did receive a response from John Wahren, the company's chief scientific officer. Presently, its a matter of determining a time when we can speak. Given the thin drug pipelines most of big pharma has these days, I suspect that they will have little problems finding a partner. Meanwhile, as Diane recently reported, Novo's new "baby" is Liraglutide to treat type 2, oh, and less we forget, another long-acting insulin analog that supposedly does not cause weight-gain. But relax, Lilly will sell you drugs for retinopathy and nerve damage, so big pharma has it all under control!
Posted at 12:21PM on Aug 23rd 2007 by Scott